greeksoup/ stock research
Stock research / United States / Funds / Nextech Invest Ltd.

Nextech Invest Ltd.

CIK 1595430 · latest 13F filed 14 August 2026 · Read the filing on EDGAR

Nextech Invest Ltd. reported 15 US-listed holdings worth $2.11 billion in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Revolution Medicines, Inc. (67.6%), Parabilis Medicines Inc. Com (6.1%) and Relay Therapeutics Inc. (6.0%). Against the quarter before, it opened 2 positions, added to 3, trimmed 1 and sold out of 4.

Filed before as Nextech Invest, Ltd..

Reported holdings$2.11B+48.3% on Q1 2026
Positions15-2 on Q1 2026
The largest ten98.0%of its reported holdings
Latest 13FQ2 2026filed 14 August 2026
Where the money is
OpenedAdded toHeldTrimmed
RVMD67.6%PBLS6.1%RLAY6.0%TYRA5.4%ALMS4.7%ORIC3.7%KYMR1.5%ZYME1.4%GLUE0.9%ARVN0.8%CTMX0.8%SLN

The 14 largest of its 15 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.

Reported holdings, quarter by quarter
Q1 2025: $430.3 million in 15 positions$430MQ1 25Q2 2025: $528.4 million in 16 positions$528MQ2 25Q3 2025: $657.0 million in 15 positions$657MQ3 25Q4 2025: $1.03 billion in 16 positions$1.03BQ4 25Q1 2026: $1.42 billion in 17 positions$1.42BQ1 26Q2 2026: $2.11 billion in 15 positions$2.11BQ2 26

What the fund reported holding at each quarter's end; hover a bar for the number of positions

What it did on the quarter

Opened 2Added 3Held 9Trimmed 1Sold out 4
Opened: 2Added: 3Held: 9Trimmed: 1Sold out: 4

Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held

Opened 2

  1. Parabilis Medicines Inc. Com PBLS$127.6 million
  2. Engene Therapeut ENGN$4.0 million

Added to 3

  1. Relay Therapeutics Inc. RLAY+1.2 million shares · +23%
  2. Monte Rosa Therapeutics Inc. GLUE+456,916 shares · +150%
  3. Arvinas Inc. ARVN+583,319 shares · +108%

Trimmed 1

  1. Tyra Biosciences Inc. TYRA-502,276 shares · -12%

Sold out of 4

  1. Tango Therapeutics Inc. TNGX$152.0 million last quarter
  2. Cullinan Therapeutics Inc. CGEM$16.2 million last quarter
  3. Engene Holdings Inc. ENGN$15.8 million last quarter
  4. Ars Pharmaceuticals Inc. SPRY$4.9 million last quarter

What it holds

CompanySharesValueOf its bookChange in shares
Revolution Medicines, Inc. RVMD7,601,087$1.42 billion67.55%no change
Parabilis Medicines Inc. Com PBLS4,663,176$127.6 million6.06%new
Relay Therapeutics Inc. RLAY6,776,506$126.8 million6.02%+1,250,000
Tyra Biosciences Inc. TYRA3,553,585$113.5 million5.39%-502,276
Alumis Inc. ALMS3,540,998$99.6 million4.73%no change
Oric Pharmaceuticals Inc. ORIC7,162,637$77.6 million3.68%no change
Kymera Therapeutics Inc. KYMR278,896$32.0 million1.52%no change
Zymeworks Inc. ZYME1,113,946$29.1 million1.38%no change
Monte Rosa Therapeutics Inc. GLUE761,153$18.4 million0.87%+456,916
Arvinas Inc. ARVN1,122,713$17.1 million0.81%+583,319
Cytomx Therapeutics Inc. CTMX4,449,932$16.7 million0.79%no change
Silence Therapeutics PLC SLN952,400$10.5 million0.50%no change
Corvus Pharmaceuticals Inc. CRVS450,000$6.7 million0.32%no change
Context Therapeutics Inc. CNTX7,419,355$4.1 million0.20%no change
Engene Therapeut ENGN2,324,943$4.0 million0.19%new
Every US-listed position in the fund's 13F for the quarter ended 30 June 2026, by the value it reported.
Read moreChange is shares against its 13F for the quarter before; the 4 it sold out of are in the box above.